Hypomagnesemia in hemodialysis patients: Role of proton pump inhibitors

American Journal of Nephrology

Volumn 39, Issue 3, 2014, Pages 204-209

  Alhosaini, Mohamad ^a   Walter, James S ^a   Singh, Sanjay ^a,b   Dieter, Robert S ^a   Hsieh, Annming ^a   Leehey, David J ^a  

^a HINES VA HOSPITAL   (United States)

^b EAST WEST UNIVERSITY   (United States)

Author keywords

Hemodialysis; Magnesium; Proton pump inhibitors

Indexed keywords

ALBUMIN; CALCIUM; FUROSEMIDE; MAGNESIUM; OMEPRAZOLE; PANTOPRAZOLE; PARATHYROID HORMONE; PHOSPHORUS; SERUM ALBUMIN; PHOSPHATE; BICARBONATE; ELECTROLYTE; PROTON PUMP INHIBITOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CATABOLISM; DIABETES MELLITUS; DIALYSATE; DISEASE ASSOCIATION; DRUG USE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROTEIN INTAKE; TREATMENT DURATION; CONTROLLED STUDY; MIDDLE AGED; AGED; BLOOD; CHEMISTRY; COMPLICATION; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL;

ADMINISTRATION, ORAL; AGED; BICARBONATES; ELECTROLYTES; HUMANS; LINEAR MODELS; MAGNESIUM; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK;

EID: 84895672137     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000360011     Document Type: Article

References (44)

1. Coburn JW, Popovtzer MM, Massry SG, Kleeman CR: The physicochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med 1969; 124: 302-311.
2. Massry SG: Magnesium homeostasis in patients with renal failure. Contrib Nephrol. Basel, Karger, 1984, vol 38, pp 175-184.
3. Cunningham J, Rodríguez M, Messa P: Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. Clin Kidney J 2012; 5(suppl 1):i39-i51.
4. Gonella M, Ballanti P, Della Rocca C, et al: Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 1988; 14: 240-245.
5. Fleming LW, Lenman JAR, Stewart WK: Effect of magnesium on nerve conduction velocity during regular dialysis treatment. J Neurol Neurosurg Psychiatry 1972; 35: 342-355.
6. Graf H, Kovarik I, Stummvoll H: Disappearance of uremic pruritus after lowering dialysate magnesium concentration. Br Med J 1979; 2: 1478-1479.
7. Delmez JA, Kelber J, Norword KY, et al: Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996; 49: 163-167.
8. Spiegel DM, Farmer B, Smits G, et al: Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr 2007; 17: 416-422.
9. Spiegel DM: The role of magnesium binders in chronic kidney disease. Semin Dial 2007; 20: 333-336.
10. Tzanakis IP, Papadaki AN, Wei M, et al: Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008; 40: 193-201.
11. De Francisco AL, Leidig M, Covic AC, et al: Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25: 3707-3717.
12. Navarro JF, Macia ML, Gallego E, et al: Serum magnesium concentration and PTH levels. Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease? Scand J Urol Nephrol 1997; 31: 275-280.
13. Gonella M, Buzzigoli G, Bencivelli W, Bartolini V, Betti G: The determination of whole blood magnesium concentration in uremics on chronic dialysis. Nephron 1981; 28: 88-89.
14. Nilsson P, Johansson SG, Danielson BG: Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. Nephron 1984; 37: 25-29.
15. Truttmann AC, Faraone R, Von Vigier RO, Nuoffer JM, Pfister R, Bianchetti MG: Maintenance hemodialysis and circulating ionized magnesium. Nephron 2002; 92: 616-621.
16. Kelber J, Slatopolsky E, Delmez JA: Acute effects of different concentrations of dialysate magnesium during high-efficiency dialysis. Am J Kidney Dis 1994; 24: 453-460.
17. Navarro JF, Mora C, Jimenez A, Torres A, Macia M, Garcia J: Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 1999; 34: 43-48.
18. Saha H, Harmoinen A, Pietila K, Morsky P, Pasternack A: Measurement of serum ionized versus total levels of magnesium and calcium in hemodialysis patients. Clin Nephrol 1996; 46: 326-331.
19. Ejaz AA, McShane AP, Gandhi VC, Leehey DJ, Ing TS: Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution. Perit Dial Int 1995; 15: 61-64.
20. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y: Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-244.
21. Kanbay M, Yilmaz MI, Apetrii M, et al: Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 2012; 36: 228-237.
22. Markaki A, Kyriazis J, Stylianou K, et al: The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients. PLoS One 2012; 7:e52350.
23. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y: Hypomagnesemia is a significant predictor of cardiovascular and noncardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-181.
24. Perazella MA: Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int 2013; 83: 553-556.
25. Bai J, Hausman E, Lionberger R, Zhang X: Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium. Mol Pharm 2012; 9: 3495-3505.
26. Danziger J, William JH, Scott DJ, et al: Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83: 692-699.
27. Walser M: The separate effects of hyperparathyroidism. Hypercalcemia of malignancy, renal failure, and acidosis on the state of calcium, phosphate, and other ions in plasma. J Clin Invest 1962; 41: 1454-1471.
28. Massry SG, Coburn JW, Kleeman CR: Evidence for suppression of parathyroid gland activity by hypermagnesemia. J Clin Invest 1970; 49: 1619-1629.
29. Ferment O, Garnier PE, Touitou Y: Comparison of the feedback effect of magnesium and calcium on parathyroid hormone secretion in man. J Endocrinol 1987; 113: 117-122.
30. Anast CS, Mohs JM, Kaplan SL, Burns TW: Evidence for parathyroid failure in magnesium deficiency. Science 1972; 177: 606-608.
31. Duran MJ, Borst GC III, Osburne RC, Eil C: Concurrent renal hypomagnesemia and hypoparathyroidism with normal parathormone responsiveness. Am J Med 1984; 76: 151-154.
32. Mennes P, Rosenbaum R, Martin K, Slatopolsky E: Hypomagnesemia and impaired parathyroid hormone secretion in chronic renal disease. Ann Intern Med 1978; 88: 206-209.
33. Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J, et al: Low vs. standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19: 1587-1593.
34. Pletka P, Bernstein DS, Hampers CL, Merrill JP, Sherwood LM: Relationship between magnesium and secondary hyperparathyroidism during long-term hemodialysis. Metabolism 1974; 23: 619-630.
35. Parsons V, Papapoulos SE, Weston MJ, Tomlinson S, O'Riordan JL: The long-term effect of lowering dialysate magnesium on circulating parathyroid hormone in patients on regular haemodialysis therapy. Acta Endocrinol (Copenh) 1980; 93: 455-460.
36. Wei M, Esbaei K, Bargman JM, Oreopoulos DG: Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease? Int Urol Nephrol 2006;38:317-322.
37. Navarro JF, Mora C, Macia M, Garcia J: Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients. Perit Dial Int 1999; 19: 455-461.
38. Cho MS, Lee KS, Lee YK, et al: Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low magnesium peritoneal dialysate. Korean J Intern Med 2002;17:114-121.
39. O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V: Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet 1986; 1: 880-882.
40. Pham PC, Pham P-MT, Pham SV, Miller JM, Pham PT: Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-373.
41. Spiegel DM, Farmer B: Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial Int 2009; 13: 453-459.
42. Turgut F, Kanbay M, Metin MR, et al: Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008; 40: 1075-1082.
43. Kyriazis J, Kalogeropoulou K, Bilirakis L, et al: Dialysate magnesium level and blood pressure. Kidney Int 2004; 66: 1221-1231.
44. Elsharkawy M, Youssef A, Zayoon M: Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates. Hemodial Int 2006; 10:S16-S23.